Here’s a situation:
• Two anti-diabetic medicines.
• Different Active Pharmaceutical Ingredients (APIs)
• Different companies.
• But brand names that sound deceptively close.
In a recent matter before the Delhi High Court, Macleods Pharmaceuticals Ltd. (prior user of ALRISTA) secured an injunction against Alkem Laboratories Ltd. over the mark ALSITA.
What made this case critical was not just trademark similarity — but patient safety.
Both products catered to diabetic patients. While their compositions differed, the Court emphasized that in the pharmaceutical industry, even a slight phonetic or structural similarity can be dangerous, especially in verbal prescriptions, rural markets, or among elderly patients.
Relying on the Supreme Court’s landmark ruling in Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd., the Court reiterated that medicinal products demand a far stricter “no-confusion” standard than ordinary consumer goods.
Two important legal principles stood out:
Marks are compared as a whole (Anti-Dissection Rule). You cannot justify similarity by isolating parts of the name.
Registration is not everything. A prior user — even with a pending or opposed application — can enforce strong common law rights.
For pharma companies, this decision reinforces a larger business truth:
A trademark clearance search is not a procedural checkbox before filing. It is a risk management exercise tied to public health, brand equity, and regulatory exposure.
In highly competitive therapeutic segments like diabetes, cardiac, or oncology; phonetic overlap is common. But common industry practices (like deriving names from APIs or house marks) do not shield you from injunctions.
Before your next product launch, ask:
- Have we evaluated phonetic similarity across the market, not just identical marks?
- Have we assessed co-prescription risks?
- Is the mark defensible in a passing-off action even if registration is delayed?
In pharma, the cost of rebranding post-launch is far higher than the cost of pre-launch diligence.
Our IP practice works closely with pharmaceutical companies to conduct high-scrutiny clearance analysis, opposition strategy, and enforcement planning specifically tailored for Class 5 products.
If you’re planning a new brand launch this quarter, it may be worth stress-testing the name before the market, or a competitor, does.
